SecBot SecBot
Biotech Drug Report Generated Sep 11, 2026

STRO-006

STRO·Sutro Biopharma, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical (IND submitted/planned; Phase 1 initiation guided for Q3 2026)
Time to market
Unknown, years away. If Phase 1 begins on schedule (Q3 2026 guidance), first human safety data would likely come in 2027; any approval would be many years later, assuming the program survives early trials.
Why 2/10
The next hard, dated catalyst is Phase 1 initiation, which Sutro guided for Q3 2026 (per the August 12, 2026 earnings release), an operational milestone rather than a data binary, and on an asset that is one of several pipeline candidates behind lead program STRO-004, so the share-price impact within ~12 months is modest.
Actionable Insight NEUTRAL

Watch for the company's confirmation that STRO-006 has entered Phase 1 (guided for Q3 2026), an operational milestone, not a data readout. The defining catalyst for Sutro's share price is STRO-004's expansion-cohort data (H1 2027 per the Q2 2026 release risk list), so treat STRO-006's near-term impact as modest pipeline news flow, not a binary.

Price Chart

Loading chart...

Executive Summary

STRO-006 is Sutro Biopharma's preclinical, ITGB6 (integrin beta-6)-targeting antibody-drug conjugate (ADC). At AACR 2026 (April 19, 2026) it showed dose-dependent antitumor activity in non-small-cell lung cancer and head-and-neck cancer models, and the company guided that it is "on track for Phase 1 initiation in Q3 2026" in its August 12, 2026 earnings release. It is one of several next-generation ADC candidates (STRO-004, the Phase 1 tissue-factor lead, and STRO-227, a PTK7 dual-payload ADC) and carries no human data yet, so its value to STRO shareholders is real but distant, an option on the platform rather than a near-term binary.

How It Works

STRO-006 is an antibody-drug conjugate (ADC), a targeted cancer therapy built like a guided missile. One part is an antibody that homes in on ITGB6 (integrin beta-6), a protein found on the surface of certain tumors, and the other part carries a chemotherapy "payload." The antibody binds to cancer cells that express ITGB6, delivering the toxin directly to the tumor instead of flooding the whole body. Sutro's platform makes these molecules in engineered cells, which the company says allows precise control of where the drug attaches. Preclinical data presented at AACR 2026 showed dose-dependent tumor shrinkage in mouse models of non-small-cell lung cancer and head-and-neck cancer. No human data exist yet.

Trial Status

STRO-006 is in preclinical development. At AACR 2026 (April 19, 2026) Sutro presented dose-dependent antitumor activity in NSCLC and head-and-neck cancer models with an IND submission planned for 2026 (per that release). In its Q2 2026 earnings release (August 12, 2026), the company said STRO-006, described there as an "ITGB6-targeting ADC", was on track for Phase 1 initiation in Q3 2026. No clinical trial record for STRO-006 appeared in SecBot's ClinicalTrials.gov-ingested pipeline data, consistent with it not having started human dosing yet.

The Two-Sided Case

▲ Bull Case4
Platform validation: STRO-006 is one of three next-gen ADCs (STRO-004, STRO-006, STRO-227) that AACR 2026 preclinical data showed with 'robust antitumor activity and favorable safety profiles', positive data reinforce confidence in Sutro's conjugation platform
Specific positive preclinical signal: STRO-006 demonstrated dose-dependent antitumor activity in NSCLC and head-and-neck cancer models, per the AACR 2026 press release
Clear near-term execution milestone: company guided STRO-006 Phase 1 initiation for Q3 2026 in its August 12, 2026 release, so the program is moving toward the clinic on schedule
Company-level support: analyst consensus on STRO is strong_buy with a mean price target of $47.23 vs ~$18 current price (implied upside ~180%); cash runway guided to at least Q2 2028, funding the pipeline
▼ Bear Case5
Preclinical stage, no human data: STRO-006 has not entered a clinical trial, preclinical mouse-model activity frequently fails to translate to patients
Not the lead program: STRO-006 is a smaller part of a multi-program pipeline; STRO-004 (Phase 1, tissue-factor ADC) is the primary value driver, so STRO-006 news alone moves STRO shares less
A Phase 1 start is an operational milestone, not a data readout, no efficacy binary until first clinical data, likely well into 2027
Intense ADC competition: the AACR 2026 release itself flags intensifying competition in the ADC space (e.g., TROP2/PTK7 programs), and ITGB6-targeting is not a de-risked, first-in-field area
Dilution risk: Sutro filed an S-3 shelf allowing up to $300M of securities, including a ~$100M ATM, future equity raises could dilute holders as pipeline costs accumulate

Upcoming Catalysts

  • Confirmation of STRO-006 Phase 1 initiation (on track for Q3 2026 per the August 12, 2026 earnings release)
  • IND submission for the STRO-227 PTK7 dual-payload ADC (targeted for 2026), which the company groups with STRO-006 as next-gen platform validation
  • STRO-004 Phase 1 expansion-cohort data (H1 2027 per Q2 2026 filing risk notes), the pipeline event with the most share-price impact

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sutro Biopharma, Inc. PRESS-RELEASE STRO ·Originating report

Sources · 3

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 sec.gov